Bellicum Discontinues Phase 1/2 Trials and Initiates Evaluation of Strategic Alternatives
14 mars 2023 16h30 HE
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, March 14, 2023 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), today announced its decision to discontinue its ongoing Phase 1/2 clinical trials evaluating the safety and...
Bellicum Presents Early Phase 1 Results for BPX-601 in Prostate Cancer at ASCO GU Cancers Symposium
16 févr. 2023 07h30 HE
|
Bellicum Pharmaceuticals, Inc.
Biochemical and radiographic responses reported in first two cohorts of dose escalation in heavily pre-treated metastatic castration-resistant prostate cancer (mCRPC) patients PSA50 or greater...
Bellicum Pharmaceuticals to Present Early Phase 1 Results for BPX-601 in Prostate Cancer at ASCO 2023 Genitourinary Cancers Symposium
19 janv. 2023 07h30 HE
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that an...
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 oct. 2022 16h05 HE
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity...
Bellicum Reports Second Quarter 2022 Financial Results and Provides Operational Update
11 août 2022 16h02 HE
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial...
Bellicum Reports First Quarter 2022 Financial Results and Provides Operational Update
12 mai 2022 16h05 HE
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, May 12, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial...
Bellicum Reports Fourth Quarter 2021 Financial Results and Provides Operational Update
24 mars 2022 16h05 HE
|
Bellicum Pharmaceuticals, Inc.
- Confirmed partial response in one of the first three metastatic castration-resistant prostate cancer (mCRPC) patients treated with BPX-601 in Phase 1/2 study - - Favorable safety profile observed...
Bellicum Regains Compliance with Nasdaq Continued Listing Requirements
13 déc. 2021 16h05 HE
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that it has...
Bellicum Announces Positive Interim Data from Phase 1/2 GoCAR-T® Studies, Secures $35 Million Private Placement Equity Financing Priced at Market
06 déc. 2021 07h30 HE
|
Bellicum Pharmaceuticals, Inc.
- Confirmed partial response observed in one patient in first cohort of metastatic castration-resistant prostate cancer (mCRPC) patients treated with BPX-601 - - Favorable safety profile observed in...
Bellicum Reports Third Quarter 2021 Financial Results and Provides Operational Update
04 nov. 2021 16h05 HE
|
Bellicum Pharmaceuticals, Inc.
- Entered into additional licensing agreement with The University of Texas MD Anderson Cancer Center for use of CaspaCIDe® safety switch technology - - Charity Scripture, MS, PharmD, appointed Chief...